COVID Countermeasures

Biodefense Headlines – 27 April 2025

News Scan April 27, 2025

This week’s topics include a consensus on the Pandemic Treaty, a Marburg vaccine Phase II trial, legislation to increase stockpile readiness for anthrax bioterrorism, and the EU updating its medical…

Moderna Secures Contract with European Union for COVID-19 Vaccines

Allucent Awarded BARDA Contract to Accelerate Next-Generation COVID-19 Booster Vaccines

Regeneron Awarded $325M for Development of Next-Gen COVID-19 Monoclonal Antibody Therapy

Project NextGen: HHS Awards $1.4B for COVID Countermeasure Development

RedHill Biopharma Highlights Federal Medical Countermeasure Investments

Molnupiravir Blocks SARS-CoV-2 Transmission in Animal Study

Antivirals, Some Antibodies, Work Well Against BA.2 Omicron Variant of COVID-19 Virus

U.S. Purchases 600,000 Courses of Eli Lilly Monoclonal Antibody That Works Against Omicron

Israel is Rolling Out Fourth Doses of COVID Vaccines to Everyone. Should Others Follow?

Preclinical Studies Support Army’s Pan-Coronavirus Vaccine Development Strategy

Does AstraZeneca’s COVID Vaccine Give Longer-Lasting Protection Than mRNA Shots?

Why Moderna Won’t Share Rights to the COVID-19 Vaccine with the Government That Paid for Its Development

Birmingham Biotech and University of Birmingham Partner on Covid-19 Anti-viral Nasal Spray

Nose Sprays, Needle-Free Patches, Durable Immunity: Towards the Next Generation of COVID Vaccines

Vaccination Offers Higher Protection Than Previous COVID-19 Infection

A Pediatrician Explains How Pfizer’s Covid-19 Vaccine for Ages 5 to 11 Was Tested for Safety and Efficacy

Ivermectin: Misuse Against COVID Risks Undermining Its Use for Other Diseases

Navigating New Federal Rules on ‘Mix-and-Match’ Vaccine Booster Shots

Poison Control Centers Still Seeing Spike in Calls for Misuse of Bleach and Antiseptics for COVID

Data Shows Continued Vulnerability of Vaccinated Blood Cancer Patients to COVID-19

Biodefense Headlines – 27 April 2025